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S314 Poster Session IIWhen used as therapy for hematopoietic malignances, allogeneic
bone marrow transplantation (BMT) relies on the graft-versus leu-
kemia (GVL) effect to eradicate residual tumor cells through
immunologic mechanisms. However, graft-versus-host-disease
(GVHD) is a potentially lethal complication of allogeneic BMT.
Thus, inhibition of GVHD, while preserving GVL and protective
responses against infectious agents, can enhance the therapeutic
potential of BMT. GVHD is initiated by alloreactive donor T cells
that recognize mismatched major (MHC) and/or minor (MiHA)
histocompatibility antigens and cause severe damage to hematopoi-
etic and epithelial tissues. Protein kinase C theta (PKCq) is a key
regulator of T cell-receptor signaling. We show here that T cell
responses triggered by Listeria or following administration of anti-
gen plus microbial adjuvant are relatively well preserved in the ab-
sence of PKCq. In contrast, we demonstrate an essential
requirement for PKCq in alloreactivity and GVHD induction. Fur-
thermore, absence of PKCq raises the threshold for T cell activa-
tion, which selectively impacts alloresponses. Most importantly,
PKCq
-/- T cells retain both the ability to respond to virus infection
and induce GVL post BMT. These findings validate PKCq as
a potentially unique therapeutic target that is required for
GVHD induction but not for GVL or protective responses to
infectious agents.425
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Advances in clinical trials for treatment of chronic GVHD have
been hampered by slow accrual of patients (pts) and by inconsistency
and limitation of historical systems for grading used prior to the 2005
NIH consensus criteria for diagnosis and classification of chronic
GVHD (Filipovich AH et al BBMT 2005;11:945-956). In an effort
to foster collaboration and expand the network for future clinical tri-
als in chronic GVHD, a Brazil-Seattle consortium was established in
2008 to conduct chronicGVHDstudies in Brazil. The Brazil-Seattle
chronic GVHD consortium included 15 multidisciplinary partici-
pants (i.e., hematopoietic cell transplant (HCT) physicians, derma-
tologist, dentist, psychiatrist, psychologist, physiotherapist and one
data manager) from 5 Brazilian institutions and two experts in
chronic GVHD from Seattle. The consortium held monthly tele-
conferences and met at least twice yearly during national and inter-
national HCT and Hematology meetings in Brazil and USA. After
training and translation of theNIH consensus criteria tools into Por-
tuguese, the group initiated a feasibility study using theNIH consen-
sus criteria after approval by each of the 5 participating centers’
institutional review boards. So far, 34 pts with NIH chronic
GVHD after allogeneic HCT in Brazil have been enrolled between
June 2006 and May 2009 and prospectively followed. Of the 34 pts
with NIH chronic GVHD, 26 (76%) met the overlap syndrome sub-
category and 8 (24%) the classic subcategory. The overall severity of
NIH chronic GVHDwas moderate in 21 pts (62%) and severe in 13
pts (38%). The median time from HCT to onset of NIH chronic
GVHD overlap syndrome subcategory was 5.9 months (2.5-10) and
from transplant to NIH chronic GVHD classic subcategory was 7.3
months (3.0-16). At a median follow up of 16.5 months, the overall
survival was 70%. At least 5 pts were enrolled from each center. In
conclusion we demonstrate the feasibility of the NIH consensus cri-
teria for the diagnosis and scoring of chronicGVHD in a prospective
Brazilian multicenter study and, more importantly, in establishing
a collaborative HCT network in Brazil that offers new opportunities
for future intervention, validation, and biomarkers clinical trials in
chronic GVHD.426
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Introduction:Graft-versus-host disease (GVHD) is the most com-
mon complication of allogeneic hematopoietic cell transplantation
(alloHCT) and may affect the transplant outcome. Its incidence is
higher when the preparative regimen used is a non-myeloablative
and the stem cell’s source is peripheral blood after mobilization.
Objective: To demonstrate the 10 years incidence of GVHD in 2
Mexican transplant centers using peripheral hematopoietic stem
cell transplantation (PHSCT) in related donors after non-myeloa-
blative conditioning.
Patients andmethods:Three hundred and fifty six patients with he-
matological and non-hematological malignancies that underwent
PHSCT after non-myeloablative conditioning between October
1998 and November 2008 were included. The age ranged between
1 and 71 years (median of 29). Two hundred and nineteen patients
were men and 137 women. They received cyclosporine 4 mg/kg
per day and intramuscular methotrexate 5 mg/m2 in days +1, +3,
+5 and +11 for GVHD prophylaxis.
Results: Three hundred and fourteen (88%) patients were suc-
cessfully engrafted. One hundred and fifty six patients (49%) de-
veloped acute and/or chronic GVHD. Of this last number of
patients, 68 (44%) developed acute GVHD, 44 (28%) developed
chronic GVHD, and 44 (28%) developed both. Twenty three
percent (26) of the patients who developed acute GVHD were
grade III or IV, and 35% (31) of chronic GVHD patients pre-
sented in the extensive way. GVHD was the cause of dead in 33
patients (12%), even when immunosuppressive therapy (high
dose steroids and rituximab) was used. Last death was 24 months
ago; subsequently, alemtuzumab was included in GVHD
treatment.
Conclusion: The incidence of acute and chronic GVHD in our pa-
tients is lower than the reported in the literature, even though the
source of hematopoietic stem cells was peripheral blood. The mor-
tality rate has decreased due to the introduction of new are more ag-
gressive immunosuppressive agents like alemtuzumab.427
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Granulocyte-macrophage colony stimulating factor (GM-CSF)
is a growth factor regulating proliferation and differentiation of
hematopoietic stem and progenitor cells. Murine GM-CSF
(mGM-CSF) has a very short half-life and pegylation of mGM-
CSF (peg-mGM-CSF) has been shown to prolong its half-life.
Based on our clinical observations that patients transplanted
with stem cell products mobilized by GM-CSF have a lower inci-
dence of acute GvHD, we hypothesized that peg-mGM-CSF may
be protective of acute GvHD in a MHC mismatched murine
model.
We have shown that C57/Bl6 mice treated with peg-mGM-
CSF led to increased CFU-C by 26.5 fold compared to PBS
treated mice (n5 6, 95% CI5 10.25-42.73). (ASH 2009) In
addition, we observed that peg-mGM-CSF increased
CD4 + FoxP3 + Tregs in both blood and spleen by 2 fold.
(p\0.05) (ASH 2009) This effect was sustained out to 4 days af-
ter the last dose of peg-mGM-CSF. Importantly, the function of
these peg-mGM-CSF Tregs, as measured in a MLR was found to
be equivalent to Tregs from PBS treated control mice (n5 3,
p5 0.27) (ASH 2009)
To assess the in vivo impact of peg-mGM-CSF on graft versus
host disease, we used the C57/Bl6/ Balb/c acute GvHD model.
